Scholarlink

<p>To determine whether intraoperative tranexamic acid (TXA) administration reduced intraoperative blood loss in patients undergoing large meningioma resection. Patients undergoing large meningioma resection face a high risk of significant blood loss. While TXA reduces blood loss and transfusion requirements in many non-neurosurgical procedures, its effect on patients undergoing supratentorial large meningioma resection remains unclear. This study was a single-center randomized double-blind trial. 228 patients having elective resections of supratentorial meningiomas with diameters ≥ 5&#xa0;cm were enrolled between February 2022 and January 2024. Patients were randomly assigned 1:1:1 to high-dose TXA (20&#xa0;mg/kg followed by a continuous infusion of 5&#xa0;mg/kg/h), low-dose TXA (a single bolus of 20&#xa0;mg/kg), or saline placebo. Anesthesiologists, neurosurgeons, and outcome assessors were all fully blinded to treatment. Our primary outcome was clinically estimated blood loss. Between February 2022 and January 2024, a total of 228 patients were randomized. The baseline was similar in each group. Median estimated blood loss was 400mL (interquartile range (IQR), 200 to 775 mL) with high-dose TXA, 425 mL (IQR, 220 to 1000 mL) with low-dose TXA, and 400 mL (IQR, 220 to 1000 mL) in the placebo group (<i>P</i> = 0.875). Other secondary outcomes did not differ significantly from any pairs of treatment groups. Intraoperative TXA administration was not associated with a statistically significant reduction in intraoperative blood loss or transfusion requirements in patients undergoing resection of large supratentorial meningiomas.</p><p><b>Trial registration:&#xa0;</b>ClinicalTrials.gov identifier NCT05230381. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of tranexamic acid on blood loss in patients undergoing resection of large meningioma: a randomized clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月11日

查看全文
  • Shu Li,
  • Minying Liu,
  • Liyong Zhang,
  • Yue Ren,
  • Yaru Wu,
  • Xueke Yin,
  • Min Zeng,
  • Dabiao Zhou,
  • Daniel I. Sessler,
  • Yuming Peng

摘要

To determine whether intraoperative tranexamic acid (TXA) administration reduced intraoperative blood loss in patients undergoing large meningioma resection. Patients undergoing large meningioma resection face a high risk of significant blood loss. While TXA reduces blood loss and transfusion requirements in many non-neurosurgical procedures, its effect on patients undergoing supratentorial large meningioma resection remains unclear. This study was a single-center randomized double-blind trial. 228 patients having elective resections of supratentorial meningiomas with diameters ≥ 5 cm were enrolled between February 2022 and January 2024. Patients were randomly assigned 1:1:1 to high-dose TXA (20 mg/kg followed by a continuous infusion of 5 mg/kg/h), low-dose TXA (a single bolus of 20 mg/kg), or saline placebo. Anesthesiologists, neurosurgeons, and outcome assessors were all fully blinded to treatment. Our primary outcome was clinically estimated blood loss. Between February 2022 and January 2024, a total of 228 patients were randomized. The baseline was similar in each group. Median estimated blood loss was 400mL (interquartile range (IQR), 200 to 775 mL) with high-dose TXA, 425 mL (IQR, 220 to 1000 mL) with low-dose TXA, and 400 mL (IQR, 220 to 1000 mL) in the placebo group (P = 0.875). Other secondary outcomes did not differ significantly from any pairs of treatment groups. Intraoperative TXA administration was not associated with a statistically significant reduction in intraoperative blood loss or transfusion requirements in patients undergoing resection of large supratentorial meningiomas.

Trial registration: ClinicalTrials.gov identifier NCT05230381.